The global market for human umbilical vein endothelial cells (HUVECs) is expected to develop steadily between 2021 and 2031, according to a report by the highly regarded consulting firm Fact.MR. According to the report, significant developments in genetic engineering and biotechnology are creating new growth markets for the treatment of severe diseases, notably in fields like oncology.
According to GLOBOCAN data, there will be 19.3 million new instances of cancer worldwide in 2020, and 10 million people will die from it. Breast cancer makes for almost a quarter of all cases of cancer that are diagnosed annually. As a result, healthcare practitioners are using cutting-edge therapeutic strategies, expanding the growth opportunities for human umbilical vein endothelial cells.
Manufacturers are focusing the majority of their efforts in important areas including Asia Pacific, China, and India. These nations have experienced an unheard-of expansion of their current healthcare infrastructure over time. This is mostly due to the large population base, which necessitates the provision of cutting-edge healthcare for a variety of chronic and infectious diseases.
For critical insights on this market, request for More Info – http://For critical insights on this market, request for More Info –
Key Takeaways from Market Study
- Through 2031, sales of pooled donor-derived HUVECs are anticipated to increase.
- A highly promising application for HUVEC-based therapy will be oncology.
- The U.S. will provide the market with a variety of revenue streams, including angiogenesis, cancer, and the treatment of CVD.
- Demand in India is being driven by the extensive expansion of biotechnology and cell culture studies.
Competitive Landscape
Leading HUVEC suppliers are Lonza Group AG, PromoCell- Human Centered Science, Merck & Co. KGaA, Thermo Fisher Scientific, Lifeline, and Corning Inc., according to Fact.profile. MR’s The market looks to be very consolidated because there are so few service suppliers.
- In May 2021, Merck & Co. announced 40 abstracts, seven oral presentations and seven poster discussions from company and investigator sponsored studies and external collaborations for its oncology treatment furtherance, an initiative which will likely provide tailwinds to its HUVEC portfolio.
- In January 2021, PromoCell received the EXCiPACTTM certification scheme for pharmaceutical excipients to Good Manufacturing Practice (GMP) standards, which implied that the company can provide tailor-made cell culture media and reagents based on each client’s end user requirements.
How Bright are HUVEC Growth Prospects across the U.S.?
The use of HUVEC-based therapies to treat cardiovascular disorders is growing quickly in the United States. HUVECs have proven to be a highly effective model for studying human endothelium and are valuable in analysing the pathophysiological pathways involved in the beginning of CVDs, according to a number of studies.
Additionally, the diagnosis and therapy of numerous tumours are increasingly using this strategy. Additionally, these cells are being used in angiogenesis to explore the patterns of ovulation, inflammation, and tumour progression.
